Kentucky Department of Insurance <u>Pharmacy Benefit Manager Review Guide</u>

PBM ENTITY NAME	Incorporation/Formation Date			
PBM Entity ID #:	Date of Receipt:	FEIN:		
UR Registration # (if applicable):	Website Address			
Address of Home Office:	c	ity State	Zip Code	
Business Address:	c	ity State	Zip Code	
Mailing Address:	P.O. BoxC	ity State	Zip Code	
Phone Number Fax Num	nber Bu	siness E-Mail Address		
Contact PersonCont	act's Phone Number	Contact's E-mail address		
PBM Coordinator Received:	FOR D	EPARTMENT USE C	ONLY	
PBM Coordinator Initial Review Completed:				
Suspense/Objection Letter Sent:				
Response Received from PBM:				
Completion of PBM Health Requirements:	Date of Health Review Completed		Reviewer signature	

Administration & Operation	Compliant	Need Additional Information RE:	Policy Reference	REC
KRS 304.17A-162 (1) (a) PBM IDENTIFY SOURCES & ESTABLISH APPEALS PROCESS RE: MAC PRICING	compliant	morniation RE.	Kererence	REQ U I R
Have a policy that PBM shall identify sources used to calculate drug reimbursement and establish a process to appeal and resolve disputes regarding maximum allowable cost pricing. 806 KAR 17:575 Process for MAC appeals process and process for the review of complaint associated with MAC appeal and requirements for the cost listings made available by a PBM.				IREMENT
KRS 304.17A-162 (1) (b) APPEAL PROCESS & 806 KAR 17:575				S
Have a policy with detailed description of the MAC Pricing Dispute Appeal Process to be used by contracted pharmacies, pharmacy services and administration organizations of group purchasing organization, including the appeals policy and procedure, pursuant to KRS.17A-162 (1) (b) and 806 KAR 17:575.				
806 KAR 17:575 (2) PBM shall establish a MAC pricing appeal process where a contracted pharmacy or the pharmacy's designee may appeal if (a) The maximum allowable cost established for a drug reimbursement is below the cost at which the drug is available for purchase by pharmacists and pharmacies in Kentucky from national or regional wholesalers licensed in Kentucky by the Kentucky Board of Pharmacy; or (b) The pharmacy benefit manager has placed a drug on the maximum allowable cost list in violation of KRS 304.17A-162(8).				
Right to appeal limited to 60 days following initial claim and PBM shall accept an appeal on or before 60 days of initial claim per 806 KAR 17:575 (2) (a)				
Per 806 KAR 17:575 (2)c) A provision allowing a contracted pharmacy, pharmacy service administration organization or group purchasing organization, to initiate the appeal process, regardless if an appeal has previously been submitted by a pharmacy or the pharmacy's designee outside of Kentucky, by contacting the pharmacy benefit manager's designated contact person electronically, by mail, or telephone. If the appeal process is initiated by telephone, the appealing party shall follow up with a written request within three (3) days.				
Per 806 KAR 17:575 (3) The pharmacy benefit manager's maximum allowable cost pricing appeal process shall be readily accessible to contracted pharmacies electronically through publication on the pharmacy benefit manager's website, and in either the contracted pharmacy's contract with the pharmacy benefit manager or through a pharmacy provider manual distributed to contracted pharmacies, pharmacy service administration organizations, and group purchasing organizations.				

Per 806 KAR 17:575 (5) The pharmacy benefit manager shall investigate, resolve, and respond to the appeal within ten (10) calendar days of receipt of the appeal. Upon resolution, the pharmacy benefit manager shall issue a written response to the appealing party that shall include the following: (a) The date of the decision; (b) The name, phone number, mailing address, email address, and title of the person making the decision; and (c) A statement setting forth the specific reason for the decision, including specific requirements for appeals denied and granted. (Listed below)	
Detailed description of the MAC Pricing Dispute Appeal Process to be used by contracted pharmacies, pharmacy services and administration organizations of group purchasing organization, including the appeals policy and procedure, pursuant to KRS.17A-162 (1) (b). Appeals process should include following provisions: Right to appeal limited to appeal received on or before 60 days following initial claim; The appeal shall be investigated and resolved by PBM within 10 calendar days; The PBM shall respond to all appeals in a manner approved by the department If an appeal is denied the PBM shall provide the following: a.) the reason for the denial per KRS 17A-162 and additional requirements for 806 KAR 17:575 including (a) The date of the decision; (b) The name, phone number, mailing address, email address, and title of the person making the decision; and (c) A statement setting forth the specific reason for the decision, including: (i) The NDC or the NDC of a therapeutically equivalent drug as defined in KRS 304.17A-162(9) of the same dosage, dosage form, and strength of the appealed drug and (ii) identify the source where (NDC) may be purchased from the Kentucky licensed wholesaler offering the drug at or below MAC on the date of fill the reason for the denial ((C) and where it may be purchased by contracted pharmacies)	
KRS 304.17A-162 (2) (a-f) APPEALS GRANTED FOR PRICE UPDATES	
KRS 304/17A-162 (a) and 806 KAR 17:575 (5)(c)(1) If the appeal is granted: Per 806 KAR 17:575 (5) The pharmacy benefit manager shall investigate, resolve, and respond to the appeal within ten (10) calendar days of receipt of the appeal. Upon resolution, the pharmacy benefit manager shall issue a written response to the appealing party that shall include the following: (a) The date of the decision;	
(b) The name, phone number, mailing address, email address, and title of the person making	
the decision; and	
(c) A statement setting forth the specific reason for the decision, including: KRS 304/17A-162 (a) and 806 KAR 17:575 (5)(c)(1) If the appeal is granted:	
(i) The amount of the adjustment to be paid retroactive to the initial date of service to the	
appealing pharmacy, (which is the date appealed drug was dispensed);	

Effective: 11/1/2021 3

(ii) The drug name, national drug code, and prescription number of the appealed drug;	
(iii) The appeal number assigned by the pharmacy benefit manager, if applicable	
PLUS <u>(a-f of statute 162)</u> items listed below.	
☐ If a price update is warranted as a result of an appeal granted the PBM shall:	
☐ A.) make the change in the maximum allowable cost to the initial date of service	
the appealed drug was dispensed;	
\square B.) adjust the maximum allowable cost of the drug for the appealing pharmacy and	
for all other contracted pharmacies in the network of that PBM that filled a	
prescription for patients covered under the same health benefit plan to the initial	
date of service the appealed drug was dispensed;	
☐ C.) individually notify all other contracted pharmacies in the network of that PBM	
that a retroactive maximum allowable cost adjustment has been made as a result of	
a granted appeal effective to the initial date of service the appealed drug was	
dispensed;	
☐ D.) adjust the drug product reimbursement for contracted pharmacies that resubmit	
claims to reflect the adjusted maximum allowable cost if applicable to their	
contract;	
☐ E.) allow the appealing pharmacy and all other contracted pharmacies in the	
network that filled prescriptions for patients covered under the same health benefit	
plan to reverse and resubmit claims and receive payment based on the adjusted	
maximum allowable cost from the initial date of service the appealed drug was	
dispensed; and	
☐ F.) make retroactive price adjustments in the next payment cycle.	
806 KAR 17:575 (8) A pharmacy benefit manager shall submit the maximum allowable cost pricing	
appeal process and a template response satisfying the requirements of subsection (5) of this section	
to the department for review and approval. 806 KAR 17:575(8)	
KRS 304.17A-162 (3) NATIONAL DRUG SOURCES USED TO ESTABLISH MAC FOR REIMBURSEMENT	
Identify the national drug pricing compendia or sources used to obtain drug price data (in a manner	
established by administrative regulations promulgated by the department) for every drug for which	
the PBM establishes a maximum allowable cost to determine the drug product reimbursement.	
Section 6. Data Source Availability. Each pharmacy benefit manager shall identify electronically or	
within contracts to all contracted pharmacies the national drug pricing compendia or sources used to	
obtain drug price data for those drugs subject to maximum allowable cost provisions. If any changes	
are made to the data sources following the execution of a contract, the pharmacy benefit manager	
shall individually notify the contracted pharmacies of the changes either through correspondence	
submitted electronically, facsimile, or mail courier. KRS 304.17A-162(3)	
KRS 304.17A-162 (4) EACH DRUG SUBJECT TO MAC & ACTUAL MAC	
Identify the location of the PBM's comprehensive list of every drug subject to MAC for each drug and	
the actual maximum allowable cost for each drug.	

Make available the PBM's comprehensive list of every drug subject to MAC for each drug and the actual	
maximum allowable cost for each drug. Please submit a screenshot of your website portal showing	
compliance.	
Section 4. Maximum allowable cost list availability and format. (1) The pharmacy benefit manager shall	
make available to the contracted pharmacy a comprehensive list of drugs subject to maximum allowable	
cost pricing.	
(2) The comprehensive maximum allowable cost pricing list shall:	
(a) Be a complete listing by drug in an electronically accessible format, unless, upon a pharmacy's	
written request the list be provided in a paper or other agreed format within two (2) business days upon	
receiving the necessary information required for each list requested;	
(b) Identify the applicable health plan for which the pricing is applicable;	
(c) Be electronically searchable and sortable by individual drug name, national drug code, and generic	
code number;	
(d) Contain data elements including the drug name, national drug code, per unit price, and strength	
of drug;	
(e) List a specific maximum allowable cost for each drug that will be reimbursed by the pharmacy	
benefit manager;	
(f) Provide the effective date for that maximum allowable cost price; and	
(g) Provide the date the maximum allowable cost list was updated.	
(3) The pharmacy benefit manager shall retain in accordance with subsection (2)(a) of this section	
historical pricing data for a minimum of 120 days. KRS 304.17A-162(4)	
KRS 304.17A-162 (5) & 304.2-165 REQUESTED INFO TO RESOLVE APPEAL PROVIDED TO DEPARTMENT	
Have a policy that upon request, information that is needed to resolve an appeal shall be made	
available to the department within 15 calendar days and if the department is unable to obtain	
information from the PBM appeal shall be granted to the appealing pharmacy. KRS 304.17A-162(5) &	
304.2-165	
KRS 304.17A-162 (6) UPDATE MAC PRICING EVERY 7 DAYS & NOTIFY CONTRACTED PHARMACIES	
Have a policy and procedure used for updating MAC pricing (for every drug PBM establishes MAC to	
determine reimbursement) every 7 calendar days and shall immediately utilize the updated MAC in	
calculating the payments made to all contracted pharmacies (and the PBM's ability to provide	
notification to all contractors. <i>This update must be every 7 calendar days from the change in pricing,</i>	
not a once weekly update. KRS 304.17A-162(6)	
KRS 304.17A-162 (7) & 806 KAR 17:575 WEEKLY UPDATES TO MAC & ACTUAL COST NOTIFICATIONS	
Have a policy and procedure indicating PBMs ability to provide notification to all contracted	
pharmacies to the pharmacists the weekly updates to the list of drugs subject to maximum allowable	
cost and the actual maximum allowable cost for each drug.	
Section 5. Weekly Updates to Maximum Allowable Cost Price List.	
(1) Pharmacy benefit managers shall send to all contracted pharmacies one (1) weekly update to the	
maximum allowable cost price list.	
(2) The weekly undate shall include the intermation below for all drugs added removed or changed	
(2) The weekly update shall include the information below for all drugs added, removed, or changed in price since the last weekly update:	

Effective: 11/1/2021 5

(a) Be in an electronically accessible format, unless, upon written request by the pharmacy the update		
be provided in paper or other agreed format within two (2) business days of receipt of the request from		
the contracted pharmacy;		
(b) Identify the basis for each drug's inclusion on the update;		
(c) If a drug is added to the maximum allowable cost list, the maximum allowable cost price shall be		
indicated;		
(d) Identify all drugs removed from the maximum allowable cost list;		
(e) If a change in the maximum allowable cost price is made, include the old price, and new price;		
(f) Identify the drug name, national drug code, generic code number, and the applicable health		
benefit plan information; and		
(g) Identify the effective date of the change.		
Please submit a screenshot of your website portal showing compliance.		
KRS 304.17A-162(7) & 806 KAR 17:575		
KRS 304.17A-162 (8) DRUG PRODUCTS & TEEs SUBJECT TO MAC ARE AVAILABLE		
Ensure every drug subject to PBM's maximum allowable costs are:		
☐ A.) Generally available for purchase by pharmacists and pharmacies in Kentucky from a		
national or regional wholesaler licensed in Kentucky by the Kentucky Board of Pharmacy;		
☐ B.) Not obsolete, temporarily unavailable, or listed on a drug shortage list; and		
☐ C1.) Drugs that have an "A" or "B" rating in the most recent version of the United States		
Food and Drug Administration Approved (USDA) Drug Products with Therapeutic Equivalence		
Evaluations(TEE), also known as the Orange Book; or		
☐ C2.) Drugs that have a "NR" or NA" rating or have a similar rating by a nationally recognized		
reference. <u>KRS 304.17A-162(8)</u>		
KRS 304.17A-162 (9) REIMBURSEMENTS ARE FOR SPECIFIC DRUG PRODUCTS & TEEs		
Have a policy to ensure that reimbursement for a drug subject to maximum allowable cost is based		
solely on specific drug and drugs that are therapeutically equivalent if the therapeutically equivalent		
drugs are listed in the most recent version of the Orange Book (which is USDA Approved Drug		
Products with Therapeutic Equivalence Evaluations). KRS 304.17A-162(9)		
KRS 304.17A-162 (10) REIMBURSEMENT FOR "B" DRUG PRODUCTS & TEEs		
Have a policy to ensure that reimbursement for a "B" rated drug subject to maximum allowable cost		
is based solely on specific drug and drugs that are not therapeutically equivalent to a "B" rating in the		
most recent version of the Orange Book. KRS 304.17A-162(10)		
KRS 304.17A-162 (11) REIMBURSEMENT FOR "NR" OR"NA" DRUG PRODUCTS & TEEs		
Have a policy to ensure that reimbursement for a "NR" or "NA" rating or similar rating by a nationally		
recognized reference subject to maximum allowable cost is based solely on that specific drug and		
other drugs with a "NR" or "NA" rating or similar rating by a nationally recognized reference that		
meets criteria for therapeutic equivalence used in the Orange Book. KRS 304.17A-162(11)		
KRS 304.17A-162 (12) REIMBURSEMENT FOR DRUG PRODUCT WITHOUT TEE		
Have a policy to ensure that reimbursement for a drug subject to maximum allowable cost is based		
solely on that drug if there is no other therapeutically equivalent drug. KRS 304.17A-162(12)		
KRS 304.17A-162 (13) REIMBURSEMENT FOR DRUG PRODUCTS ARE AVAILABLE		

	T	1	
Have a policy to ensure that reimbursement for a drug subject to maximum allowable cost is not			
based on a drug that is obsolete, temporarily unavailable, listed on a drug shortage list, or that cannot			
be lawfully substituted. KRS 304.17A-162(13)			
KRS 304.17A-167 STANDARDS FOR ELECTRONIC PRIOR AUTHORIZATIONS			
Have a process for electronically requesting and transmitting prior authorization for a drug by			
providers that meets the requirement of the most recent National Council for Prescription Drug			
Programs SCRIPT standards for electronic prior authorization transactions adopted by the US Dept. of			
Health and Human Services. KRS 304.17A-167			
45 CFR 156.122 EXCEPTIONS POLICY & POLICY TO ACCESS RETAIL PHARMACY			
Have an <i>Exceptions Policy</i> which allows an enrollee, designee, or prescribing provider to gain access to			
clinically appropriate drugs not otherwise covered by the plan, and includes a standard procedure. <u>45</u> <u>CFR 156.122</u>			
Have an Exceptions Policy which allows an enrollee, designee, or prescribing provider to gain access to			
clinically appropriate drugs not otherwise covered by the plan, and includes an expedited procedure.			
Have a policy that explains the process that gives the ability to access prescriptions from an in-network			
retail, unless special handling or another reason proves that the prescription cannot be provided by a			
retail pharmacy.			
OTHER POLICIES POLICY RE: PHARMACY & THERAPEUTICS COMMITTEE			
Have a policy and procedure relating to the resolution of MAC pricing complaints which are filed with			
the Kentucky Department of Insurance, including timeframes and sample appeal response letter.			
Include a sample of following letters/templates:			
a.) appeal granted from PBM to pharmacist			
b.) appeal denial from PBM to pharmacist			
c.) individual notification informing all contracted pharmacies of an adjustment in reimbursement as a result of a granted appeal.			
Have a policy explaining any Pharmacy and Therapeutics committee membership standards and duties,			
including how often the committee meets, structure, and the decision-making process.			
Section 7 of KAR 17:575: Annual report. All pharmacy benefit managers licensed to do business in			
Kentucky shall transmit at least annually by March 31 to the department a Pharmacy Benefit Manager			
Annual Report. Please find the Annual Report <u>here.</u> Or, it can be submitted electronically if you have an			
<u>eServices account.</u>			
All supporting documentation including but not limited to Provider Agreement templates if any			
responsibilities are delegated and Pharmacy Agreement templates. Please note that any delegated			
entities must be Kentucky Licensed prior to the approval of your submitted renewal.			
☐ Pharmacy Agreement Template Included			
□ Delegated Provider Agreement Template Included			
OTHER REQUIREMENTS MAY BE VERIFIED BY LICENSURE			
Have proof of financial responsibility in the amount of one million dollars (\$1,000,000).			

Have proof of registration with the Kentucky Secretary of State's office in order to do business in Kentucky.		
Have \$1,000 non-refundable fee (KRS 304.9-200(4)), made payable to the Kentucky State Treasurer.		
The fee may also be paid through <u>eServices</u> . To pay application fees through eServices, a "Business "		
Entity – License Administrator" account is required. Allow 48 hours after receipt of application to		
pay these fees under "pay pending fees" from the menu.		